

CLINICAL EXPERIENCE WITH DOLUTEGRAVIR IN A TERTIARY HOSPITAL

L. Menéndez Naranjo, M. Almanchel Rivadeneyra, C. Muñoz Contreras, A. Mancebo González, MJ. Sánchez Garre. A. de La Rubia Nieto.
Hospital Clínico Universitario Virgen de la Arrixaca



BACKGROUND

Dolutegravir has been marketed in Spain last year. Due to its recent approval, it seems interesting to describe our clinical experience


PURPOSE

To evaluate the use of dolutegravir in patients with HIV infection treated in a tertiary hospital.

METHODS

Observational retrospective study of all patients who started therapy with dolutegravir in our centre since its introduction in January 2015 until June 15. Data was collected from electronic clinical history and hospital's electronic prescribing software. The following variables were collected: sex, age, type of patient (naive, virological failure, switch strategies), viral load (VL) pre-treatment, after 4 weeks, 12 and 24 weeks.

RESULTS



CONCLUSIONS

- ✓ Dolutegravir was used primarily as a strategy for simplification to avoid drug interactions and to improve/prevent antirretrovirals toxicity.
- ✓ Most patients got undetectable VL after 12 weeks and treatment was well tolerated